bioihbjkbjnl/mcl2 huggingface dataset:
Kinesiological Taping and Aerobic Exercise in Women With Primary Dysmenorrhea:
Condition: Primary Dysmenorrhea; Kinesics; Aerobic Exercise
MeSH terms: Dysmenorrhea
Study type: Interventional

Summary: 
      Dysmenorrhea is defined as the pain and discomfort of women during the menstrual period.
      Kinesiological taping (KT) and aerobic exercise (AE) are effective methods for dysmenorrhea.
      The purpose of this study is to investigate the effects of KT and AE on pain, attitude,
      depression, and quality of life in women with dysmenorrhoea. Forty-five women with
      dysmenorrhea wıll randomly be divided into three groups as KT group (n=15), AE group (n=15)
      and control group (n=15). In KT Group, 6 sessions of KT will be applied, starting on the 14th
      day of the menstrual cycle and 2 times per week for 3 weeks until the end of the cycle. In
      the AE group, walking and climbing stairs will be given during the menstrual cycle, 3 days a
      week, 45 minutes. No application will be applied to the control group. All groups will be
      evaluated with Beck Depression Scale (BDS), Mcgill Pain Questionnaire (MPQ), Menstrual
      Attitude Scale (MAS), and Short Form- 36 (SF-36) before and after the intervention.
    


Intervention name(s): Kinesiological taping; Aerobic exercise
Intervention type(s): Behavioral; Behavioral
Intervention description(s): In KT Group, 6 sessions of KT were applied, starting on the 14th day of the menstrual cycle and 2 times a week for 3 weeks until the cycle ended.; In the AE group, walking and climbing stairs were given during the menstrual cycle, 3 days a week, 45 minutes.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: Primary Dysmenorrhea; Kinesiological Taping; Aerobic Exercise
A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia
Condition: Asymptomatic Hyperuricemia
MeSH terms: Hyperuricemia
Study type: Interventional
Phase: Phase 1

Summary: 
      The main purpose To evaluate the safety and tolerability of pegloticase in subjects with
      asymptomatic hyperuricemia by single intravenous infusion at different doses, and to provide
      a basis for multiple doses of Pegloticase in subjects with asymptomatic hyperuricemia.

      A secondary purpose To evaluate the pharmacokinetics, pharmacodynamics and immunogenicity of
      Pegloticase with single-pass intravenous drip in subjects with asymptomatic hyperuricemia.

      Exploratory purpose Plasma uricase activity (pUox) analysis of pegloticase with single-pass
      intravenous drip in subjects with asymptomatic hyperuricemia.
    

Detailed description: 
      To evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics analysis of
      pegloticase in subjects with asymptomatic hyperuricemia.

      This is a phase I randomized, double-blind, placebo-controlled and dose-increasing single
      dosing study. Five dose groups of 1, 2, 4, 8 or 12 mg were planned to explore the most
      appropriate dose and to provide a basis for multiple doses of Pegloticase in subjects with
      asymptomatic hyperuricemia.
    

Intervention name(s): SIBP-R002; Dexamethasone or Methyl prednisolone; Diphenhydramine; Placebo
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): SIBP-R002: injection; strength: 1, 2, 4, 8 or 12 mg; dose escalation and the first group is 1mg (intravenous infusion, 5 groups, the first group consisted of four people, and the other groups consisted of eight).; Intravenous infusion, 5mg or 1~2mg/kg. These were administered within 30 minutes prior to infusion of the experimental drug.; 10mg, intramuscular injection.These were administered within 30 minutes prior to infusion of the experimental drug.; The same volume of placebo as SIBP-R002: injection; strength: the same volume of placebo as SIBP-R002 of 1, 2, 4, 8 or 12 mg (intravenous infusion, 5 groups, the first group consisted of one people, and the other groups consisted of two). The rule and dose of placebo were the same as SIBP-R002.
Intervention MeSH terms: Diphenhydramine; Promethazine; Dexamethasone; Prednisolone; Methylprednisolone Acetate; Methylprednisolone; Methylprednisolone Hemisuccinate; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: This is a phase I randomized, double-blind, placebo-controlled and dose-increasing single dosing study.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Hyperuricemia; Pegloticase; Safety; Tolerability
Autologous Peripheral Blood Stem Cell Transplantation With In Vivo Purging as an Alternate Stem Cell Transplantation Program for Pts w/AML in 1st & 2nd Complete Remission w/no HLA Matched Related Donor
Condition: Leukemia, Monocytic, Acute
MeSH terms: Leukemia, Monocytic, Acute
Study type: Interventional

Summary: 
      Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem
      cell transplantation program for pts w/AML in 1st & 2nd complete remission w/no HLA matched
      related donor
    


Intervention name(s): Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation
Intervention type(s): Drug
Intervention description(s): Autologous PBSCT
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: AML in 1st & 2nd complete remission w/no HLA matched related donor
Effect of NWT-03 on Blood Pressure - Part 1
Condition: Blood Pressure
Study type: Interventional

Summary: 
      Part 1 of the study will assess the effect of 1g, 2g and 5g doses of NWT-03 on systolic and
      diastolic blood pressure in a cross-over designed study in healthy adults with normal, high
      normal and mild hypertension. Based on results from this study, one dose will be selected for
      a placebo controlled parallel study assessing a single dose of NWT-03 on systolic and
      diastolic blood pressure and endothelial function in a similar population.
    


Intervention name(s): NWT-03, an egg-white protein hydrolysate; Placebo
Intervention type(s): Dietary Supplement; Dietary Supplement
Intervention description(s): For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given; A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Prevention
Effects of Kinesio Taping vs Jones Technique on Myofascial Trigger Points in Cervicalgia.
Condition: Cervicalgia
MeSH terms: Neck Pain
Study type: Interventional

Summary: 
      A large number of workers in different sectors suffer from musculoskeletal neck disorders,
      which are the most common work-related illness in Europe. A multitude of combinations of
      techniques can be used to treat these conditions, including recorded film and the Jones
      technique. This pilot study examines the efficacy of Kinesio taping and the Jones technique
      in improving pain, joint range of motion and muscle tension in active subjects with latent
      myofascial trigger points. A clinical trial was conducted with 38 patients with neck pain.
      The sample was randomly distributed into three groups: a Jones technique group, a kinesio
      taping group and a combined therapy group in which both techniques were performed. The
      duration of treatment was 4 weeks, with a follow-up of 2 weeks. Cervical spine joint range of
      motion, pain and functional disability were assessed with the goniometer, the visual analogue
      scale, the pressure algometer and the cervical disability index.
    


Intervention name(s): Jones technique; Kinesiotape
Intervention type(s): Procedure; Device
Intervention description(s): is a gentle soft tissue manipulation consisting of a passive procedure that positions the body in a position of comfort to release tissue that compresses or shortens the body structure (muscle contraction and joint dysfunction); KT has an S-shaped glue, which lifts the skin, thus improving blood and lymphatic circulation, with the intention of relieving pain and improving musculoskeletal diseases especially in sports
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Cervicalgia; cinta de kinesio; Técnica de Jones; fisioterapia; puntos de activación.
Physiotherapy-led Outpatient Clinic for Patients With Spondyloarthritis
Condition: Spondylarthritis; Spondylitis, Ankylosing; Spondylarthropathies; Sacroiliitis; Arthritis, Psoriatic
MeSH terms: Spondylitis; Spondylarthritis; Arthritis, Psoriatic; Spondylitis, Ankylosing; Sacroiliitis; Spondylarthropathies
Study type: Interventional

Summary: 
      The purpose of this study is to determine whether patients with spondyloarthritis are more
      satisfied with a physiotherapy-led outpatient clinic than usual care and whether there is a
      difference between patients in a physiotherapy-led outpatient clinic and those in usual care
      regarding disease activity, function and mobility.
    


Intervention name(s): Physiotherapy follow-up
Intervention type(s): Other
Intervention description(s): Physiotherapy consultation every 4 months containing assessment of the spine and its mobility, including axial joints, assessment of the patients activity profile.
Instruction in home-exercises and recommendations for optimization of activity profile. Information regarding the disease and the importance of physical activity and exercise.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Physiotherapy; Outpatient clinic
Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy
Condition: Polypoidal Choroidal Vasculopathy
MeSH terms: Polypoidal Choroidal Vasculopathy; Vascular Diseases
Study type: Interventional
Phase: Phase 4

Summary: 
      The purpose of this study is to compare the efficacy and safety of intravitreal Aflibercept
      monotherapy with the efficacy and safety of combined treatment with Aflibercept plus standard
      photodynamic therapy (PDT) with Verteporfin in age-related macular degeneration (AMD)
      patients with polypoidal choroidal vasculopathy (PCV).
    

Detailed description: 
      To compare the efficacy and safety of intravitreal Aflibercept monotherapy with the efficacy
      and safety of combined treatment with Aflibercept associated with standard photodynamic
      therapy (PDT) with Verteporfin in age-related macular degeneration (AMD) patients with
      polypoidal choroidal vasculopathy (PCV) in a proof concept study and to identify genetic
      biomarkers for the diagnosis and treatment response of PCV in Caucasians.
    

Intervention name(s): Intravitreal Aflibercept
Intervention type(s): Drug
Other intervention name(s): standard photodynamic therapy (PDT)
Intervention MeSH terms: Aflibercept
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Adipose-derived Stem Cells (ADSCs) for Knee Osteoarthritis
Condition: Knee Osteoarthritis
MeSH terms: Osteoarthritis; Osteoarthritis, Knee
Study type: Interventional
Phase: Phase 1/Phase 2

Summary: 
      1. To assess the safety of allogeneic injection of expanded ADSCs to patients with knee
           osteoarthritis

        2. To assess the efficacy of allogeneic injection of expanded ADSCs to patients with knee
           osteoarthritis
    


Intervention name(s): Elixcyte 8 ml; Hya Joint Plus; Elixcyte 4 ml; Elixcyte 2 ml
Intervention type(s): Biological; Device; Biological; Biological
Intervention description(s): ADSC 6.4*10^7 cells, allogeneic injection; Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc.; ADSC 3.2*10^7 cells, allogeneic injection; ADSC 1.6*10^7 cells, allogeneic injection
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Primary purpose: Treatment
Effects of Dehydroepiandrosterone (DHEA) in Humans
Condition: Aging
Study type: Interventional
Phase: Phase 3

Summary: 
      The purpose of this study is to determine whether bringing back the DHEA levels of older
      persons to the young range produces beneficial effects.
    

Detailed description: 
      DHEA and DHEA sulfate (DHEAS) plasma concentrations peak at about 20 years of age and decline
      rapidly and markedly after age 25 yr. DHEA is a PPAR-alpha activator. PPAR-alpha plays major
      roles in regulating lipid metabolism and controlling inflammation. DHEA also appears to have
      anabolic effects on muscle and bone. The study is designed to determine the effects of 12
      months of DHEA replacement in 65-75 year old women and men on (a) truncal and visceral fat,
      (b) insulin resistance and serum triglycerides, (c) muscle mass and strength, (d) bone
      mineral density, (e) chronic inflammation, (f) arterial-endothelium-dependent vasodilation,
      and (g) sense of well being.

      The specific aims of this study are to test the hypotheses that 12 months of DHEA replacement
      will (a) Result in significant decreases in truncal and visceral fat by shifting metabolism
      to fat oxidation and increasing energy wastage; (b) Decrease insulin resistance and decrease
      serum triglycerides; (c) Increase muscle mass and strength, by decreasing catabolic stimuli
      and increasing anabolic stimuli; (d) Increase bone mineral density by increasing anabolic
      stimuli and decreasing catabolic stimuli; (e) Reduce chronic inflammation and decrease
      pro-inflammatory cytokine production by peripheral blood mononuclear cells; (f) Improve
      arterial endothelium dependent vasodilation; and (g) Improve general sense of well being.
    

Intervention name(s): DHEA replacement
Intervention type(s): Drug
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double
Primary purpose: Treatment
Keywords: Metabolic syndrome
A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users
Condition: Healthy
Study type: Interventional
Phase: Phase 1

Summary: 
      This study will evaluate the abuse potential of ALKS 5461.
    


Intervention name(s): ALKS 5461; Buprenorphine; Placebo
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Sublingual tablets, single administration; Sublingual tablets, single administration; Sublingual tablets, single administration
Intervention MeSH terms: Buprenorphine
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: Healthy Volunteer; Abuse Liability; ALKS 5461; Alkermes
Prevenar (PCV-7) Post-Licensure Safety Study In Russia
Condition: Healthy Children After Vaccination
Study type: Observational

Summary: 
      This study is planned to monitor the local and/or systemic reactions and compatibility of
      PCV-7 with routine vaccines in the Russian National immunization schedule. Consistent with
      the observational nature of this protocol, Prevenar will be administered as standard of care.

      The aim of this study is to estimate the incidence of febrile reactions more than 38.0
      degrees Celsius, specifically (≥38 to < 39 degrees C; > 39 to < 40 degrees C and > 40 degrees
      C, and the frequency of other local or systemic reactions following vaccination with Prevenar
      (PCV-7) co-administered with other routine childhood vaccines under the conditions of routine
      daily use in the Russian Federation.
    


Intervention name(s): Non-interventional observational study
Intervention type(s): Other
Intervention description(s): Non-interventional observational study
Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Infants and Children from 3 months to 23 months at enrollment
      
Keywords: vaccine; infant; healthy subjects
Screening for the Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR FAP)
Condition: Polyneuropathy, Amyloid; Neuropathic Pain; Cardiac Failure; Orthostatic Hypotension; Gastrointestinal Disorders
MeSH terms: Gastrointestinal Diseases; Digestive System Diseases; Neuralgia; Polyneuropathies; Hypotension, Orthostatic; Amyloid Neuropathies; Hypotension; Heart Failure
Study type: Observational

Summary: 
      An International, multicenter, epidemiological observational study investigating the
      prevalence of Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR-FAP) in
      participants with small fiber polyneuropathy of no obvious etiology.
    

Detailed description: 
      Transthyretin-related Familial Amyloid Polyneuropathy (TTR-FAP) is an autosomal dominant,
      progressive neurodegenerative disease, with fatal outcome occurring within ten years after
      onset. Familial amyloid polyneuropathy (FAP) associated with mutations in the transthyretin
      (TTR) gene is the most common form of genetic amyloidosis. It accounts several thousand cases
      worldwide, with Val30Met mutation identified in most patients and with endemic foci in
      Portugal, Sweden and Japan.

      TTR FAP is caused by the systemic deposition of amyloidogenic variants of the transthyretin
      protein ((Ttr) in the extra-cellular space of tissues and result in disruption of organ
      function.The typical presentation of TTR-FAP is a progressive sensory-motor polyneuropathy,
      which usually begins with loss of thermal and pain sensation in the feet, slowly ascends up
      the limbs and is associated with variable autonomic disturbances and extra-neurological
      manifestations (especially a cardiomyopathy).

      The goal of the TRAP2.1 Study is to investigate the prevalence of Transthyretin-Related
      Familial Amyloidotic Polyneuropathy (TTR-FAP) in a cohort of 500 subjects with small fiber
      polyneuropathy of no obvious etiology, based on the subject's clinical presentation.
    

Observational model: Cohort
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        Participants diagnosed with small fiber polyneuropathy of no obvious etiology.
      
Biospecimen description: 
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (Centocard®)
    
Keywords: Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy; TTR FAP; Biomarker
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
Condition: Renal Artery Stenosis; Ischemic Nephropathy; Renovascular Disease; Chronic Kidney Disease
MeSH terms: Kidney Diseases; Renal Insufficiency, Chronic; Renal Artery Obstruction; Hypertension, Renovascular; Hypertension; Hypoxia
Study type: Interventional
Phase: Phase 1

Summary: 
      Current treatments for ARAS based on restoring blood flow alone have been unsuccessful at
      recovering kidney function. For this reason we are studying a stem cell product called
      "mesenchymal stem cells" or MSC. Mesenchymal stem cells (MSC) are grown from a person's own
      fat tissue (obtained as a fat biopsy) and infused back into the patient's own kidney.

      This study is also being done to determine if the MSC infusion prior to percutaneous
      transluminal renal angioplasty with stenting (PTRA) further enhances changes in single kidney
      blood flow and restoration of kidney function, as well as to assess the relationship between
      MSC dose and measures of kidney function.
    

Detailed description: 
      These studies include participation by human subjects using a 3-day inpatient CRU protocol at
      St. Mary's Hospital. Studies include formal measurement of blood and urinary markers of
      kidney function, BOLD MR and multidetector CT scanning. Forty-two non-diabetic patients
      between 40 and 80 years of any race or ethnicity will be recruited. All will have
      hypertension (defined as BP≥140/90 mmHg or ongoing antihypertensive drug therapy) but will
      have less than 180 mmHg to be included (with or without drug therapy). These subjects will be
      free of cardiovascular events within 3 months and will not have implanted electrical devices,
      such as a pacemaker or defibrillator. All patients will have identified large vessel
      renovascular disease (RVD) for Aims 1, 2 and 3. At least 10% of these subjects will be of
      African-American descent (self-identified) and recruited in collaboration with the University
      of Mississippi under the direction of Dr. Luis Juncos and the University of Alabama under the
      direction of Dr. David Calhoun. For completion of Aims 2 and 3, a three-day evaluation will
      be repeated between three and four months later, and ongoing safety and imaging studies will
      be performed up to 24 months after MSC administration. Participants in these protocols will
      undergo transvenous kidney biopsy under the direction of Drs. McKusick and Misra and their
      colleagues in Interventional Radiology. All subjects for these studies will complete the
      research plan at Mayo Clinic, Rochester, Minnesota.
    

Intervention name(s): Mesenchymal stem cell; Mesenchymal stem cell delivery with stent placement
Intervention type(s): Drug; Procedure
Intervention description(s): Intra-arterial infusion of the single-dose MSC; Intra-arterial stent placement after Mesenchymal stem cell infusion
Other intervention name(s): Mesenchymal stem cell delivery
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine
Condition: Idiopathic Precocious Puberty
MeSH terms: Puberty, Precocious
Study type: Interventional
Phase: Phase 4

Summary: 
      Our study used a randomized controlled trial to validate the clinical efficacy of a
      combination of traditional Chinese and Western medicine in the treatment of children with
      rapid progressive central precocious puberty.
    

Detailed description: 
      In the research, 164 subjects diagnosed with rapid progressive idiopathic precocious puberty
      are randomly divided into Group Ziyinxiehuo Granules and Megestrol Acetate Tablet（82
      cases）and Group Gonadotrophin ( 82 cases). Patients in Group Ziyinxiehuo Granules and
      Megestrol Acetate Tablet are treated with ziyinxiehuo Granules and megestrol acetate tablet ,
      whereas the Group Gonadotrophin received with gonadotrophin releasing hormone agonist, and
      all the subjects in two groups are continuously treated for 6 months.
    

Intervention name(s): Ziyinxiehuo Granules Herbs; Megestrol Acetate Tablet; Leuprorelin Acetate 3.75mg Injection
Intervention type(s): Drug; Drug; Drug
Intervention description(s): 1 pack of Ziyinxiehuo granules Herbs is administered after dissolved, 2 times per day after a meal.; the dose is 6-8mg/d, three times per day after meals.; Usage： 80μg/kg by subcutaneous injection, every 4 weeks
Other intervention name(s): nourishing"Yin"-removing"Fire" Granules
Intervention MeSH terms: Megestrol; Megestrol Acetate; Leuprolide
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Idiopathic Precocious Puberty; Rapid Progressive; Integrative Chinese and Western Medicine; Evidence-based Medicine